SCHEMBL81243

SCHEMBL81243

CCC(O)N1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
FDPS P14324 2/20 0.36
DPP7 Q9UHL4 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 3/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.32
SLC6A3 Q01959 5/20 0.32
SLC6A2 P23975 3/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
SLC6A4 P31645 2/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27854795 1.00 MEN1 (0.39) MEN1KMT2AFDPSDPP7SMN1; SMN2
Hydrochloric Acid SCHEMBL27404843 0.97 MEN1 (0.37) MEN1KMT2AFDPSDPP7SMN1; SMN2
SCHEMBL841130 0.97
SCHEMBL3923601 0.86
SCHEMBL636365 0.86 TSHR (0.37) MEN1KMT2ATSHR
SCHEMBL22711078 0.81 OPRM1 (0.34) SMN1; SMN2SLC6A2SLC6A4
SCHEMBL1650151 0.80 SLC6A3 (0.40) MEN1KMT2ASLC6A3SLC6A2SLC6A4
SCHEMBL11543878 0.78 OPRD1 (0.38) MEN1KMT2ASMN1; SMN2SLC6A2SLC6A4
SCHEMBL18727479 0.78 ALDH1A1 (0.42) KMT2ASMN1; SMN2MAPTALDH1A1TSHR
SCHEMBL8767704 0.77 KDM4E (0.35) ALDH1A1SLC6A3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119391317-A Packaging adhesive film for light flexible component and preparation method thereof 常州斯威克光伏新材料有限公司 2025-02-07 CN claimed
CN-118059905-A Method for preparing methanol by integrating carbon dioxide trapping and hydrogenation by using Cu-based catalyst 上海陕煤高新技术研究院有限公司 2024-05-24 CN claimed
EP-3461552-B1 CARBON DIOXIDE ABSORBENT AND APPARATUS OF SEPARATING AND RECOVERING CARBON DIOXIDE TOSHIBA KK (JP) 2023-12-13 EP claimed
CN-116284848-A Method for dissolving chitosan/cellulose by using multifunctional acidic ionic liquid 南京工业大学 2023-06-23 CN claimed
CN-114014825-B Synthesis method of histamine H3 receptor antagonist telithromycin 河南师范大学 2023-06-02 CN claimed
CN-114014825-A Efficient synthesis method of histamine H3 receptor antagonist teloprolofen 河南师范大学 2022-02-08 CN claimed
US-11130858-B2 Curable compositions for cured-in-place pipes PIPEFUSION CIPP CORPORATION (US) 2021-09-28 US claimed
US-20210095114-A1 CURABLE COMPOSITIONS FOR CURED-IN-PLACE PIPES PIPEFUSION CIPP CORPORATION (US) 2021-04-01 US claimed
US-10865305-B2 Method of curing a cured-in-place liner PIPEFUSION CIPP CORPORATION (US) 2020-12-15 US claimed
US-20200291224-A1 CURABLE COMPOSITION FOR CURED IN PLACE PIPES PIPEFUSION CIPP CORPORATION (US) 2020-09-17 US claimed
US-20140243456-A1 Anhydride Accelerators for Epoxy Resin Systems AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-08-28 US claimed
EP-2710006-A1 AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2014-03-26 EP claimed
CN-103435575-A Preparation method of 1- (3- (3- (4-chlorphenyl) propoxy) propyl) piperidine hydrochloride INST PHARM & TOXICOLOGY AMMS 2013-12-11 CN claimed
WO-2012158785-A1 AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2012-11-22 WO claimed
EP-1963331-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2008-09-03 EP claimed
WO-2007070796-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2007-06-21 WO claimed
US-20030232739-A1 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist PFIZER INC. 2003-12-18 US claimed
WO-1997009376-A1 STABILIZATION SYSTEMS FOR POLYMERIC MATERIALS IN PELLET FORM CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) 1997-03-13 WO claimed
US-RE35217-E ALKALINE DEVELOPMENT OF EXPOSED NOVOLAK/O-QUINONEDIAZIDE PHOTORESIST LATENT IMAGE BASF AKTIENGESELLSCHAFT (DE) 1996-04-23 US claimed
US-4264599-A HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS CIBA-GEIGY CORPORATION (US) 1981-04-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232739-A1 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist GRIN1, GRIN2B, GRIN2A MEN1 3545/4885KMT2A 922/4885FDPS 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.